MedTrace Logo

Contribution of L-Tyrosine to Recovery From Operational Strain on Return From External Operation

NCT04549194 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2022-11-25

No results posted yet for this study

Summary

Operational conditions amplify soldier's constraints and stress factors, upsetting individual and collective adaptive landmarks. The soldier's resistance is strained by the high intensity of stressors, by the long duration of exposure and by their cumulative effect.

This may lead to a state of "operational strain" that refers to chronic stress and the allostatic load imposed by operational constraint.

The investigators believe that operational strain could manifest itself by a kind of accelerated aging of the organism due to the increased allostatic load without sufficient resource restoration (neurotransmitter precursors, partial and repeated sleep deprivation, etc.).

This aging mechanism would be reversible after a sufficient period of resource restoration (sleep, physical activity, adapted diet, etc.).

Conditions

  • Stress, Psychological

Interventions

BIOLOGICAL

Blood collection

A blood sample will be collected before during and after the treatment.

DRUG

L-Tyrosine 500 Mg

The participants will be administered 4 capsules of L-Tyrosine 500 mg per oral route daily over 1 month.

BEHAVIORAL

Psychological questionnaires

The participants will fill in several psychological questionnaires before, during and after treatment administration: * Life Event Checklist * Moral injury * Posttraumatic Checklist * Burnout Assessment Tool * State-Trait Anger Expression Inventory-2 * Ruminative Response Scale - Reconsidered * Deployment Risk and Resilience Inventory-2 * Questionnaire about tobacco use

DEVICE

Photoplethysmography

Photoplethysmography recording will be performed before during and after the treatment.

DRUG

Placebo

The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route daily over 1 month.

Sponsors & Collaborators

  • Direction Centrale du Service de Santé des Armées

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-09
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04549194 on ClinicalTrials.gov